Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium
about
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancersMesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancerMesothelin-induced pancreatic cancer cell proliferation involves alteration of cyclin E via activation of signal transducer and activator of transcription protein 3Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinomaMesothelin-Targeted CARs: Driving T Cells to Solid TumorsIsolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.fTwo novel biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma.Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms.Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicitySafety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.Controlling tumor-derived and vascular endothelial cell growth: role of the 4Ff2 cell surface antigenHE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection.A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.Mesothelin expression is a prognostic factor in cholangiocellular carcinoma.Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinomaNovel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational studyChimeric antigen receptor T cells: a novel therapy for solid tumors.Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy.Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.Amatuximab and novel agents targeting mesothelin for solid tumors.Current best practice in the evaluation and management of malignant pleural effusions.Serum mesothelin and other biomarkers: what have we learned in the last decade?Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer modelsElevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer
P2860
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
P2860
Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Characterization of the antige ...... cancers and normal mesothelium
@ast
Characterization of the antige ...... cancers and normal mesothelium
@en
Characterization of the antige ...... cancers and normal mesothelium
@nl
type
label
Characterization of the antige ...... cancers and normal mesothelium
@ast
Characterization of the antige ...... cancers and normal mesothelium
@en
Characterization of the antige ...... cancers and normal mesothelium
@nl
prefLabel
Characterization of the antige ...... cancers and normal mesothelium
@ast
Characterization of the antige ...... cancers and normal mesothelium
@en
Characterization of the antige ...... cancers and normal mesothelium
@nl
P2093
P1433
P1476
Characterization of the antige ...... cancers and normal mesothelium
@en
P2093
P407
P577
1992-01-01T00:00:00Z